Illumina, Inc. (NASDAQ:ILMN) Shares Sold by Handelsbanken Fonder AB

Handelsbanken Fonder AB cut its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 27.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 49,927 shares of the life sciences company’s stock after selling 18,587 shares during the period. Handelsbanken Fonder AB’s holdings in Illumina were worth $6,952,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Annis Gardner Whiting Capital Advisors LLC acquired a new position in shares of Illumina during the third quarter worth $30,000. VisionPoint Advisory Group LLC increased its position in shares of Illumina by 344.6% during the third quarter. VisionPoint Advisory Group LLC now owns 249 shares of the life sciences company’s stock worth $34,000 after purchasing an additional 193 shares in the last quarter. Wetzel Investment Advisors Inc. acquired a new position in shares of Illumina during the fourth quarter worth $37,000. Gradient Investments LLC increased its position in shares of Illumina by 375.0% during the fourth quarter. Gradient Investments LLC now owns 285 shares of the life sciences company’s stock worth $40,000 after purchasing an additional 225 shares in the last quarter. Finally, North Star Investment Management Corp. increased its position in shares of Illumina by 183.0% during the fourth quarter. North Star Investment Management Corp. now owns 300 shares of the life sciences company’s stock worth $42,000 after purchasing an additional 194 shares in the last quarter. 89.42% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

ILMN has been the topic of several research reports. OTR Global reissued a “mixed” rating on shares of Illumina in a research report on Wednesday, March 20th. Barclays upped their target price on Illumina from $85.00 to $100.00 and gave the company an “underweight” rating in a research report on Wednesday, April 10th. TD Cowen downgraded Illumina from an “outperform” rating to a “market perform” rating and set a $144.00 target price on the stock. in a research report on Thursday, January 4th. HSBC downgraded Illumina from a “buy” rating to a “hold” rating in a research report on Tuesday, January 16th. Finally, StockNews.com raised Illumina from a “hold” rating to a “buy” rating in a research report on Friday, February 16th. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $167.70.

Insider Activity at Illumina

In related news, CEO Jacob Thaysen purchased 7,330 shares of the firm’s stock in a transaction that occurred on Thursday, February 22nd. The shares were purchased at an average cost of $135.29 per share, with a total value of $991,675.70. Following the purchase, the chief executive officer now owns 14,861 shares of the company’s stock, valued at approximately $2,010,544.69. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.17% of the stock is currently owned by corporate insiders.

Illumina Stock Down 1.3 %

ILMN stock opened at $122.87 on Thursday. The company’s 50-day simple moving average is $132.44 and its 200-day simple moving average is $127.54. The company has a debt-to-equity ratio of 0.26, a current ratio of 1.66 and a quick ratio of 1.29. Illumina, Inc. has a 52-week low of $89.00 and a 52-week high of $228.13.

Illumina (NASDAQ:ILMN) last posted its earnings results on Thursday, February 8th. The life sciences company reported $0.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.01 by $0.13. Illumina had a negative net margin of 25.78% and a positive return on equity of 2.20%. The business had revenue of $1.12 billion for the quarter, compared to analyst estimates of $1.09 billion. During the same period in the prior year, the company posted $0.14 EPS. The company’s revenue for the quarter was up 3.6% on a year-over-year basis. As a group, equities analysts predict that Illumina, Inc. will post 0.91 earnings per share for the current year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.